Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) CEO Sells $4,585,000.00 in Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) CEO Jack A. Khattar sold 125,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the completion of the transaction, the chief executive officer now directly owns 926,172 shares of the company’s stock, valued at $33,971,988.96. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Supernus Pharmaceuticals Stock Performance

Supernus Pharmaceuticals stock opened at $36.60 on Monday. Supernus Pharmaceuticals, Inc. has a twelve month low of $24.46 and a twelve month high of $39.37. The firm has a market cap of $2.02 billion, a PE ratio of 34.21 and a beta of 0.86. The firm’s 50 day moving average price is $33.13 and its two-hundred day moving average price is $30.68.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.25. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The business had revenue of $175.70 million during the quarter, compared to analyst estimates of $157.35 million. During the same period last year, the company earned ($0.29) earnings per share. Supernus Pharmaceuticals’s quarterly revenue was up 14.2% compared to the same quarter last year. Equities analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current fiscal year.

Analysts Set New Price Targets

SUPN has been the subject of a number of research analyst reports. Piper Sandler restated a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Finally, StockNews.com upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Large investors have recently made changes to their positions in the company. GAMMA Investing LLC lifted its stake in Supernus Pharmaceuticals by 97.1% in the third quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock valued at $25,000 after acquiring an additional 398 shares during the last quarter. EntryPoint Capital LLC bought a new stake in Supernus Pharmaceuticals in the first quarter worth $43,000. Meeder Asset Management Inc. acquired a new position in Supernus Pharmaceuticals during the second quarter worth $47,000. Innealta Capital LLC bought a new position in Supernus Pharmaceuticals during the second quarter valued at about $51,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Supernus Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock worth $61,000 after buying an additional 352 shares during the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.